Vaccinial Keratitis Treated With Interferon

Jones, B. R.; Galbraith, J. E. K.; Al-hussaini, M. K.

doi:10.1016/s0140-6736(62)91908-6

Cited by 78 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All four had recieved prior chemotherapy and radiotherapy. The duration of HLIFN treatment was 5,9,14 and 16 months (average 11 months). The first signs of tumor response were noted on days 42, 51, 57 and 74 from the beginning of treatment.…”

Section: Head and Neck Squamous Cell Arcinomamentioning

confidence: 99%

See 1 more Smart Citation

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Medenica¹,

Slack²

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

The efficacy of Human 6 IFN (HLIFN) given in a pulse fashion was determined in a phase II study. Ninety-one cancer patients were evaluated (9 myeloma, 12 breast, 14 prostate, 9 melanoma, 4 renal, 6 astrocytoma, 7 ovarian, 9 large bowel, 7 gastric, 14 head and neck). They all had advanced progressive cancer that was resistant to chemotherapy and/or radiotherapy. Patients were treated by intramuscular injection of 6 X 10(2) I.U./m2 for three consecutive days every four weeks. 84 patients were evaluable. Complete clinical response was obtained in 23 patients (4 myeloma, 2 breast, 5 prostate, 1 melanoma, 1 renal, 2 astrocytoma, 2 ovarian, 2 large bowel, 1 gastric, 3 head and neck). Partial responses were observed in 35 patients (3 myeloma, 7 breast, 6 prostate, 4 melanoma, 1 renal, 2 astrocytoma, 3 ovarian, 4 head and neck). Objective responses were related (P less than 0.01) to serum IFN level, with complete and partial responses (P less than 0.01) more commonly seen in those patients whose serum IFN levels at two hours were in the range of 1000 to 1650 I.U./ml. Side effects resulting from pulse IFN were acceptable for this group of patients and consisted of fever, transient chills, malaise and asthenia, and transient thrombocytopenia and leukocytopenia. The extent of fever was directly related (P less than 0.01) to response, and was most elevated in patients who achieved objective responses. IFN administered in a pulse fashion appears to be more effective than daily IFN and merits further evaluation.

show abstract

Section: Head and Neck Squamous Cell Arcinomamentioning

confidence: 99%

“…IFN was discovered over 25 years ago. Its clinical use started in 1962 (14,15). Recent advances have led to new preparations and purification tech¬ niques, thus providing sufficient HLIFN to conduct phase I and II clinical trials in cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Medenica¹,

Slack²

1985

Cancer Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Results from a number of laboratories suggest that it may be successful in the prevention or treatment of certain viral infections in vitro as well as in infections of animals and humans (11,12,14,17,20). Although members of the herpesvirus group are relatively insensitive to the action of interferon (5,11,13), evidence suggests that interferon or interferon inducers may be efficacious in certain experimental herpetic infections.…”

mentioning

confidence: 99%

Herpesvirus hominis Infection in Newborn Mice: Treatment with Interferon Inducer Polyinosinic-Polycytidylic Acid

Kern

Overall²,

Glasgow³

1975

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Intranasal inoculation of newborn mice with Herpesvirus hominis (HVH) type 2 provides a model for disseminated herpesvirus infections of human newborn infants. Treatment of this experimental infection with polyinosinic-polycytidylic acid [poly(I:C)] significantly increased the mean survival time and markedly altered the pathogenesis of the infection. No significant protection against final mortality was observed. Poly(I:C) therapy completely inhibited detectable viral replication in all target organs tested except the brain. In the brain there was a 2-day delay in the onset of viral replication in treated animals, which correlated with the 1- to 2-day increase in mean survival time. In general, the control of HVH replication occurred in those target organs in which poly(I:C)-induced interferon was detectable. The failure of poly(I:C) to alter the final mortality of newborn mice infected with HVH appears to be primarily due to the lack of sufficient levels of interferon induced in brain tissue and the failure to prevent viral replication in this critical target organ.

show abstract

“…Results from a number of laboratories have suggested that both interferon (9,10,18) and interferon inducers (2-4, 11, 14, 15) may be used successfully in the prevention or treatment of certain viral infections in experimental animals and in humans. Although exogenous interferon has been evaluated in several clinical ' Publication no.…”

mentioning

confidence: 99%

Effect of Treatment with Exogenous Interferon, Polyinosinic Acid-Polycytidylic Acid, or Polyinosinic Acid-Polycytidylic Acid-Poly- l -Lysine Complex on Encephalomyocarditis Virus Infections in Mice

Olsen

Kern²,

Glasgow³

et al. 1976

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The effect of treatment with exogenous interferon was compared with two interferon inducers, polyinosinic acid-polycytidylic acid [poly(I:C)] and [poly(I:C)]-poly- l -lysine complex (P-L-L complex), in two model encephalomyocarditis virus infections of mice. Although both inducers stimulated the production of interferon, the peak serum levels induced by P-L-L complex were five- to eightfold greater than those induced with poly(I:C). When encephalomyocarditis virus was inoculated by either the intraperitoneal or the intranasal route, interferon and both of the inducers protected mice against mortality and prolonged the mean day of death when the compounds were given prior to or immediately after viral challenge. In general, treatment with interferon was not as successful as treatment with poly(I:C) or P-L-L complex. In these infections, P-L-L complex appeared to be the most effective agent in that successful treatment resulted when drug therapy was initiated as late as 48 h after virus inoculation. An examination of the effect of treatment on the pathogenesis of the infection indicated that protection was associated with the prevention of viremia and subsequent seeding of target organs, particularly the central nervous system.

show abstract

Vaccinial Keratitis Treated With Interferon

Cited by 78 publications

References 3 publications

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Clinical Results of Leukocyte Interferon-Induced Tumor Regression in Resistant Human Metastatic Cancer Resistant to Chemotherapy and/or Radiotherapy-Pulse Therapy Schedule

Herpesvirus hominis Infection in Newborn Mice: Treatment with Interferon Inducer Polyinosinic-Polycytidylic Acid

Effect of Treatment with Exogenous Interferon, Polyinosinic Acid-Polycytidylic Acid, or Polyinosinic Acid-Polycytidylic Acid-Poly- l -Lysine Complex on Encephalomyocarditis Virus Infections in Mice

Contact Info

Product

Resources

About